NATCO Pharma Bilan de santé
Santé financière contrôle des critères 6/6
NATCO Pharma possède un total de capitaux propres de ₹71.6B et une dette totale de ₹2.0B, ce qui porte son ratio d'endettement à 2.8%. Son actif total et son passif total sont ₹82.4B et de ₹10.9B. L'EBIT de NATCO Pharma est ₹21.9B ce qui fait que son ratio de couverture des intérêts -27.4. Elle dispose de liquidités et de placements à court terme de ₹24.6B.
Informations clés
2.8%
Ratio d'endettement
₹2.01b
Dette
| Ratio de couverture des intérêts | -27.4x |
| Argent liquide | ₹24.63b |
| Fonds propres | ₹71.57b |
| Total du passif | ₹10.88b |
| Total des actifs | ₹82.45b |
Mises à jour récentes de la santé financière
NATCO Pharma (NSE:NATCOPHARM) Seems To Use Debt Rather Sparingly
Jun 30
Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?
Jan 25Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?
Jul 16Does NATCO Pharma (NSE:NATCOPHARM) Have A Healthy Balance Sheet?
Jun 23Recent updates
NATCO Pharma (NSE:NATCOPHARM) Has Announced A Dividend Of ₹1.50
Nov 18Earnings Beat: NATCO Pharma Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Nov 15We Ran A Stock Scan For Earnings Growth And NATCO Pharma (NSE:NATCOPHARM) Passed With Ease
Oct 13NATCO Pharma Limited's (NSE:NATCOPHARM) Shares Bounce 26% But Its Business Still Trails The Market
Aug 13If EPS Growth Is Important To You, NATCO Pharma (NSE:NATCOPHARM) Presents An Opportunity
Jul 15NATCO Pharma (NSE:NATCOPHARM) Seems To Use Debt Rather Sparingly
Jun 30NATCO Pharma Limited's (NSE:NATCOPHARM) Earnings Are Not Doing Enough For Some Investors
Jun 14NATCO Pharma Limited (NSE:NATCOPHARM) Exceeded Expectations And The Analyst Consensus Has Been Reviewing Its Models
May 30Calculating The Fair Value Of NATCO Pharma Limited (NSE:NATCOPHARM)
May 09Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?
Apr 03NATCO Pharma (NSE:NATCOPHARM) Is Due To Pay A Dividend Of ₹1.25
Feb 21NATCO Pharma Limited Just Beat EPS By 223%: Here's What Analysts Think Will Happen Next
Feb 18NATCO Pharma Limited (NSE:NATCOPHARM) Surges 25% Yet Its Low P/E Is No Reason For Excitement
Feb 17Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?
Jan 25An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 37% Undervalued
Jan 09Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?
Dec 13An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 42% Undervalued
Sep 30Here's Why We Think NATCO Pharma (NSE:NATCOPHARM) Might Deserve Your Attention Today
Sep 12NATCO Pharma (NSE:NATCOPHARM) Is Paying Out A Larger Dividend Than Last Year
Aug 12Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?
Jul 16NATCO Pharma Limited (NSE:NATCOPHARM) Shares Could Be 44% Below Their Intrinsic Value Estimate
Apr 20Is NATCO Pharma Limited (NSE:NATCOPHARM) Trading At A 46% Discount?
Dec 20NATCO Pharma's (NSE:NATCOPHARM) Upcoming Dividend Will Be Larger Than Last Year's
Aug 12Does NATCO Pharma (NSE:NATCOPHARM) Have A Healthy Balance Sheet?
Jun 23Broker Revenue Forecasts For NATCO Pharma Limited (NSE:NATCOPHARM) Are Surging Higher
Jun 02Analyse de la situation financière
Passif à court terme: Les actifs à court terme de NATCOPHARM ( ₹50.0B ) dépassent ses passifs à court terme ( ₹10.1B ).
Passif à long terme: Les actifs à court terme de NATCOPHARM ( ₹50.0B ) dépassent ses passifs à long terme ( ₹792.0M ).
Historique et analyse du ratio d'endettement
Niveau d'endettement: NATCOPHARM dispose de plus de liquidités que de sa dette totale.
Réduire la dette: Le ratio d'endettement de NATCOPHARM a été réduit de 8.2% à 2.8% au cours des 5 dernières années.
Couverture de la dette: La dette de NATCOPHARM est bien couverte par le flux de trésorerie opérationnel ( 853.9% ).
Couverture des intérêts: NATCOPHARM gagne plus d'intérêts qu'il n'en paie, donc la couverture des paiements d'intérêts n'est pas un problème.